Failing Blockbuster Medicines, Eroding Operator Margins & Increased Pricing Pressures: What’s Next for Precision Medicine?
Posted 12th September 2018 by Jane Williams
The Precision Medicine and Biomarkers Leaders Summit: Europe takes place this week and in anticipation, we spoke to Unmesh Lal of Frost and Sullivan about his views on what the future holds for precision medicine and how the pharmaceutical industry has changed in recent times.
Posted 5th September 2018 by Jane Williams
I don’t need to tell you that pharma has changed, that it is still changing at speed, or that change is the new normal. I don’t need to tell you because you − more than anyone else − already know. The passing of the blockbuster era has caused uncertainty. Without the superstar drugs of old, where does the industry go next? It’s a serious challenge, but without challenge, there is no change. The answer, of course, is the scalar shift from blockbuster generic to precision medicine specific.
Posted 3rd September 2018 by Jane Williams
Brandon Allgood is the Chief Technology Officer at Numerate, as well as a co-founder. In addition to being responsible for the development of Numerate’s cloud-based machine learning platforms, Brandon runs the software & data science teams, and is the technical lead on all of the companies internal drug programs, as well as external collaborations.
Here, Brandon talks about what he thinks the future holds for AI and machine learning:
Big Data Analytics and Artificial Intelligence: 7 Design Principles to Empower Life Science Researchers
Posted 5th January 2018 by Jane Williams
Life sciences research is increasingly relying on big data analytics to drive scientific discovery. One of the contributing factors to this trend is the fact that researchers are confronted with a rapidly growing body of scientific literature and databases required to interpret experimental outcomes.
Posted 22nd December 2017 by Jane Williams
The traditional product pipeline, which information technology will compress and alter significantly in the life sciences in the coming years. Source: Wikimedia user MattBishop5 (CC BY-SA 3.0).
This article was originally published by Dassault Systèmes BIOVIA in October 2017, and is published here with permission.
Where can life science companies go operationally to maintain or create a competitive advantage? This question has been a constant in the industry since its inception, but recent advances in older technologies like Laboratory Information Management Systems (LIMS) and the appearance of promising newer technologies like the Internet of Things (IoT) have changed the nature of the answer. Which new technologies that are theoretically worthwhile have matured enough to be gracefully implemented operationally?
Posted 24th November 2017 by Jane Williams
Therapeutic interventions have traditionally been developed for patients with established pathologies and overt clinical symptoms. Many diseases however, are not tractable in later stages and therefore therapies are needed that intervene earlier in the disease continuum.
Posted 8th November 2017 by Jane Williams
The quest for magic bullets started with Paul Ehrlich. He wanted to target the syphilis bacteria without harming the patients, which led to Salvarsan. Ehrlich was a foundational thinker, and we owe him modern concepts such as receptor and pharmacophore. His impact on the field – seeking the ideal molecules – pervades drug discovery.
Posted 27th October 2017 by Jane Williams
Ever thought about how you avoid introducing “just another IT system”? How to get to the point where people work with the system joyfully and don’t mutter about the small faults or that no-one improves the system?